

“Study of D-dimer levels as short term prognostic marker in patients with acute ischemic stroke.

Name and designation of authors: Dr. Ajay V Daphale¹, Professor, Department of general medicine, Dr. PDMMC Amravati;

Dr. Miren Patel², Junior resident, Department of general medicine, Dr. PDMMC Amravati; Dr. Rohan Kalmegh³, Assistant Professor,

Department of general medicine, Dr. PDMMC Amravati;

Dr. Saurabh Lande⁴, Assistant Professor, Department of general medicine, Dr. PDMMC Amravati.

Affiliations: Department of General Medicine, Dr. PDMMC Amravati, Maharashtra state, India.

Corresponding author details:

Name: Dr. Miren Patel²

Address: Department of General Medicine, Dr. PDMMC Amravati, Maharashtra, state, India.

Telephone: 9823370781

Email: mirenpatel4@gmail.com

Abstract

Background: Elevated levels of plasma D-dimer increase the risk of ischemic stroke, stroke severity, and the prognosis of stroke patient. The plasma D-dimer level increases during blood thrombosis and degradation of fibrin, hence it is a biological marker of haemostatic abnormalities and thrombosis. Association between plasma D-dimer level and functional outcome of acute ischemic stroke is unclear hence we have undertaken study to investigate whether plasma D-dimer level is a determinant of short-term poor functional outcome in patients with acute ischemic stroke (AIS). **Methods:** Present study was cross sectional in nature conducted on 100 AIS patients. All patients fulfilling inclusion criteria and exclusion criteria were taken up for the study. **Results:** In the present study, there was strong positive correlation of Modified Rankin Scale scores in patients with AIS with D dimer level ($r=0.6$; $p=0.04$) which means patients with poor short-term outcomes had significantly raised D dimer levels.

Conclusion: Plasma D dimer level is determinant of short-term poor outcome & prognosis inpatient with acute ischemic stroke.

Key words: Plasma D dimer, Ischemic stroke, short term outcome, prognosis.

Introduction:

Elevated levels of plasma D-dimer increase the risk of ischemic stroke, stroke severity, and the prognosis of stroke patient.^{1,2} The plasma D-dimer level increases during blood thrombosis and degradation of fibrin, hence it is a biological marker of haemostatic abnormalities and thrombosis.³ D-dimer is a soluble fibrin degradation final product and derived from the cross-linked fibrin network as it undergoes plasmin-mediated degradation.

Elevated D-dimer concentrations could be associated with cerebral venous sinus thrombosis, acute pulmonary embolism, spontaneous intracerebral hemorrhage, long-term neurologic outcomes in arterial ischemic stroke.⁴ Markers of fibrin formation were found to be significantly increased after acute ischemic stroke and transient ischemic attack (TIA); their levels significantly differed according to stroke subtype.⁵

As only few studies have been carried out, the association between plasma D-dimer level and functional outcome of acute ischemic stroke is unclear. The aim of this study is to investigate whether plasma D-dimer level is a determinant of short-term poor functional outcome in patients with acute ischemic stroke (AIS).

Objectives

To estimate levels of D-dimer in patients of acute ischemic stroke and to determine the association of elevated levels of D-dimer with short-term outcomes.

Materials and Methods

This was a longitudinal follow up study conducted over a period of six months from December 2022 to May 2023. We have taken approval from the Institutional Ethical committee of the medical college and this study is consistent with all the ethical standards. Written informed consent was taken from all study subjects.

All patients fulfilling inclusion criteria and exclusion criteria admitted in ICU of Dr. PDMMC and tertiary care hospital were taken up for the study until fulfilling the required sample size.

A total of 100 male and female patient with acute ischemic stroke (AIS) >18 years age admitted in our tertiary care hospital were recruited in the study. AIS was diagnosed according to the World Health Organization criteria combined with brain CT or MRI confirmation within 48 hours. Patients with acute hemorrhagic stroke and venous stroke, preexisting significant disability & those who did not willing to participate were excluded from study. Pre-validated, pretested, semi structured questionnaire was used as data collection tool.

Thorough systemic and general examination was done for clinical evaluation.

All participants were subjected to detailed neurological history taking (with stressing on the vascular, cardiac risk factors) and full general and neurological examination. Blood investigation (CBC, ESR, CRP, KFT, LFT, lipid profile & D-dimer), Radiological investigation (CT brain, MRI brain) were carried out. The normal range of morning plasma D-dimer concentration considered in our study was 0–0.5 mg/L. Each participant was followed up after 3 months i.e. 90 days via telephone and face to face for the assessment of short term outcomes. outcome was assessed with modified Rankin Scale (mRS). A good functional outcome was defined as an mRS score of 0–2 points, whereas a poor outcome was mRS score of 3–6 points.

1- α /2 Sample size was calculated with $n = [DEFF * Np(1-p)] / [(d^2/Z^2 * (N-1) + p*(1-p))]$ using OPENEPI software version 3. Tao Yao et al⁶ in their study of Elevated plasma D-dimer levels are associated with short-term poor outcome in patients with acute ischemic stroke, found that sensitivity of D-dimer level for detection of poor outcome was 83.8%. Considering this, with 95% confidence interval and absolute precision of 8%, sample size came out to be 82 which was rounded to 100 for convenience of calculations.

Data was entered in Microsoft Excel and analyzed using SPSS Software. Means were compared by using student t test while qualitative variables compared by using Chi square test of significance.

Results:

The present study was prospective in nature conducted on 100 acute ischemic stroke patients, on follow up assessment of outcome at 90th day by Modified Rankin Scale we have found that 42 (42%) patient was having good outcome while 58 (58%) was having poor outcome. Mean age of the patient in good outcome group was 59.3 ± 11.4 years vs 61.8 ± 10.8 years in poor outcome group & there was no significant difference between the two ($p=0.2$).

Significantly more no. of males (61.9%) had good outcome while significant no. of females (62.1%) had poor outcome ($p=0.01$). Comorbidities seen in our study were coronary artery disease, diabetes, hypertension, previous stroke, dyslipidemia. Patients with good & poor outcome did not differ significantly according to comorbidities ($p>0.05$). Two groups also did not differ as per addictions ($p>0.05$). Mean D dimer level of patients with poor outcome (1.88 ± 0.98 mg/l) was significantly raised than the patients with good outcome (0.44 ± 0.22 mg/l) ($p<0.0001$). (Table 1)

In the present study, there was strong positive correlation of Modified Rankin Scale scores in patients with AIS with D dimer level ($r=0.6$; $p=0.04$) which means patients with poor short-term outcomes had significantly raised D dimer levels. (Table 2)

Discussion:

In our study, higher plasma D-dimer level on admission was a significant independent determinant of short-term outcome at 90th day as measured by mRS (Modified Rankin Scale). 42% patient was having good outcome while 58% was having poor outcome.

Mean age of the patient in these two groups did not differ significantly ($p=0.2$). Significantly more no. of males (61.9%) had good outcome while significant no. of females (62.1%) had poor outcome ($p=0.01$). Comorbidities seen were coronary artery disease, diabetes, hypertension, previous stroke, dyslipidemia. Patients with good & poor outcome did not differ significantly according to comorbidities ($p>0.05$). Two groups also did not differ as per addictions ($p>0.05$). Mean D dimer level of patients with poor outcome (1.88 ± 0.98 mg/l) was

significantly raised than the patients with good outcome (0.44 ± 0.22 mg/l) ($p<0.0001$). Potential

confounders: age, comorbidities, addictions fortunately equally distributed between the two groups. These findings are in line with Tao Yao et al and Yosria⁶ and Al Hameed AlTaweel et al.⁷

In the present study, there was strong positive correlation of Modified Rankin Scale scores in patients with AIS with D dimer level ($r=0.6$; $p=0.04$) which means patients with poor short-term outcomes had significantly raised D dimer levels. Many of the epidemiological studies have revealed that there is a positive association between plasma D-dimer levels and stroke,⁸⁻¹⁰ stroke severity,^{11,12} infarct volume,¹³⁻¹⁵ and progression.^{16,17} This is consistent with Tao Yao et al⁶ who reported that after adjustment for potential confounding variables, higher plasma D-dimer level on admission was associated with poor outcome and Jing Zhang et al¹⁸ who noted elevated D dimer level associated with poor functional outcome at

both 30 days and 90 days.

Conclusion:

As the raised plasma D dimer levels are strongly correlated with short term poor outcome measured by Modified Rankin Scale, we can conclude that plasma D dimer level is determinant of short-term poor outcome & prognosis in patient with acute ischemic stroke.

Declaration:

There was no source of funding in our study and there was no any conflict of interest in this study.

References

1. Van den Berghe G. Endocrine evaluation of patients with critical illness. *Endocrinol Metab Clin North Am* 2003; 32: 385-410.
2. McIver B, Gorman CA. Euthyroid sick syndrome: an overview. *Thyroid* 1997; 7: 125-32.
3. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. *J Clin Endocrinol Metab* 2003; 88: 3202-11.
4. Stouthard JM, van der Poll T, Endert E, Bakker PJ, Veenhof CH, Sauerwein HP, et al. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. *J Clin Endocrinol Metab* 1994; 79: 1342-6.
5. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med*. 1992; 20(6):864-874.
6. Yao T, Tian B, Li G, Cui Q, Wang C, Zhang Q, et al. Elevated plasma D-dimer levels are associated with short-term poor outcome in patients with acute ischemic stroke: a prospective, observational study. 2019;1-9.
7. Abd Y, Hameed A, Nageeb RS, Metwally PM, Badawy AE. Role of some inflammatory biomarkers in prediction of short-term outcome in acute ischemic stroke. 2021.
8. Di Castelnuovo A, Agnoli C, de Curtis A, Giurdanella MC, Sieri S, Mattiello A, Matullo G, Panico S, Sacerdote C, Tumino R, et al. Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke. Findings from the EPICOR Study. *Thromb Haemost*. 2014;112(5):941-6.
9. Folsom AR, Gottesman RF, Appiah D, Shahar E, Mosley TH. Plasma d-Dimer and Incident Ischemic Stroke and Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. *Stroke*. 2016;47(1):18.
10. Hamatani Y, Nagai T, Nakai M, Nishimura K, Honda Y, Nakano H, Honda S, Iwakami N, Sugano Y, Asami Y, et al. Elevated Plasma D-Dimer Level Is Associated with Short-Term Risk of Ischemic Stroke in Patients with Acute Heart Failure. *Stroke*. 2018;49(7):1737-40.
11. Berge E, Friis P, Sandset PM. Hemostatic Activation in Acute Ischemic Stroke. *Thromb Res*. 2001;101(2):13-21.

12. Greco G, Stucchi C, Genedani S. Clinical severity of ischemic stroke and neural damage biomarkers in the acute setting: the STROke MARKers (STROMA) study. *Minerva Anestesiol* 2013, 79(7):750.
13. Young-Woo P, Eun-Jeong K, Ha-Young C. Correlation between Serum DDimer Level and Volume in Acute Ischemic Stroke. *Journal of Korean Neurosurgical Society*. 2011;50(2):89.
14. Zi WJ, Shuai J. Plasma D-dimer levels are associated with stroke subtypes and infarction volume in patients with acute ischemic stroke. *Plos One*. 2014;9(1):e86465.
15. Abbas NI, Sayed O, Samir S, Abeed N. D-dimer Level is Correlated with Prognosis, Infarct Size, and NIHSS in Acute Ischemic Stroke Patients. 2021.
16. Mark B, Peter L, Ann R, Lowe GDO, Stott DJ. D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. *Stroke*. 2006;37(4):1113–5.
17. Zang R, Zhang H, Xu Y, Zhang S, Liu X, Wang J, Gao Y, Shu M, Mei B, Li H. Serum C-reactive protein, fibrinogen and D-dimer in patients with progressive cerebral infarction. *Translational Neuroscience*. 2016;7(1):84–8.
18. Zhang J, Liu L, Tao J, Song Y, Fan Y, Gou M, et al. Prognostic role of early D-dimerlevel in patients with acute ischemic stroke. 2019;1–10.

Table 1 Association of short-term outcomes with baseline characteristics.

Baseline characteristic		Good Outcome (n=42)	Poor Outcome (n=58)	P
		N0. (%)	N0. (%)	
Age (years)	Mean \pm SD	59.3 \pm 11.4	61.8 \pm 10.8	0.2
Gender	Male	26 (61.9)	22 (37.9)	0.01
	Female	16 (38.1)	36 (62.1)	
Comorbidities	CAD	11 (26.2)	13 (22.4)	0.6
	DM	19 (45.2)	28 (48.3)	0.7
	HTN	32 (76.2)	42 (72.4)	0.6
	Previous stroke	06 (14.3)	08 (13.8)	0.9
	Dyslipidemia	27 (64.3)	41 (70.7)	0.5
	Obesity	17 (40.5)	24 (41.4)	0.9
	Alcohol	09 (21.4)	15 (25.9)	0.6

Addictions	Smoking	18 (42.9)	24 (41.4)	0.8
D dimer (mg/l)	Mean \pm SD	0.44 \pm 0.22	1.88 \pm 0.98	<0.0001

Table 2. Correlation of D dimer level with Modified Rankin Scale scores in patients with AIS.

D dimer level	mRS score	Pearson correlation	
Mean \pm SD	Mean \pm SD	R	P
1.16 \pm 0.7	4.3 \pm 2.89	0.6	0.04